Showing Results for
- Academic Journals (49,384)
Search Results
- 49,384
Academic Journals
- 49,384
- 1From:Radiation Oncology (Vol. 8, Issue 1) Peer-ReviewedPurpose Multimodality therapy leads to improved outcomes for adenocarcinoma of the distal esophagus and gastroesophageal junction (GEJ) over surgery alone. At our institution, adjuvant chemoradiation (chemoRT) using...
- 2From:Journal of Cardiothoracic Surgery (Vol. 8, Issue 1) Peer-ReviewedPulmonary blastoma is a rare primary lung neoplasm, in that monophasic variety is far too rare. There are no specific clinical features seen for pulmonary blastoma; computed tomography and histopathology are diagnostic....
- 3From:Expert Review of Anti-infective Therapy (Vol. 7, Issue 10) Peer-ReviewedAuthor(s): Rosa F Yeh [[dagger]] 1 , Rupali Jain 2 , Hannah R Palmer 3 The 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) was held in San Francisco (CA, USA) in September 2009....
- 4From:BMC Cancer (Vol. 22, Issue 1) Peer-ReviewedBackground Platinum-based chemoradiotherapy is the standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC). However, few studies have evaluated the efficacy of subsequent chemotherapy for...
- 5From:Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 11, Issue 6) Peer-ReviewedAuthor(s): Karim Chamie [[dagger]] 1 , Mark S Litwin 2 Keywords : bladder cancer; guideline adherence; quality of care; survival Significant progress has been made in improving the care of patients with...
- 6From:Chest (Vol. 106, Issue 6) Peer-ReviewedThe purpose of this trial (Lung Cancer Study Group [LCSG] 853) was to perform a comparative study of immediate combination chemotherapy (cyclophosphamide, doxorubicin, cisplatin [CAP]) vs delayed combination...
- 7From:Chest (Vol. 109, Issue 5) Peer-ReviewedThere is a significant potential benefit for induction chemotherapy in the management of non-small cell lung cancer (NSCLC). The real extent of such benefit is difficult to assess on the basis of available data owing to...
- 8From:Indian Journal of Medical and Paediatric Oncology (Vol. 37, Issue 4) Peer-ReviewedByline: Ulrich. Nitsche, Bo. Kong, Alexander. Balmert, Helmut. Friess, Jorg. Kleeff Pancreatic ductal adenocarcinoma is a highly aggressive disease, and medical as well as surgical therapeutic options are limited....
- 9From:BMC Cancer (Vol. 12, Issue 1) Peer-ReviewedBackground Surgery is often advocated in patients with resectable pulmonary metastases from colorectal cancer (CRC). Our study aims to evaluate peri-operative chemotherapy in patients with metastastic CRC undergoing...
- 10From:Journal of Experimental & Clinical Cancer Research (Vol. 32, Issue 1) Peer-ReviewedBackground Numerous studies have yielded inconclusive results regarding the relationship between anti-apoptotic protein Bcl-2 expression and the sensitivity to chemotherapy in the patients with breast cancer. The...
- 11From:Obesity, Fitness & Wellness WeekBy a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- OAK BROOK, Ill. - Magnetic resonance imaging (MRI) provides an indication of a breast tumor's response to pre-surgical chemotherapy...
- 12From:Chest (Vol. 109, Issue 5) Peer-ReviewedStudy objective: To determine the efficacy of methotrexate, vinblastine, and platinum chemotherapy in patients with diffuse unresectable malignant mesothelioma. Design: Patients with histologically confirmed malignant...
- 13From:Chest (Vol. 117, Issue 4) Peer-ReviewedPaclitaxel, the first of the taxanes, has exhibited unique and encouraging single-agent activity in the treatment of non-small cell lung cancer (NSCLC). Yet, with single-agent response rates approaching 25%, it was...
- 14From:Oncology Nurse AdvisorRecent trial results suggest that adding obinutuzumab to standard salvage chemotherapy appeared to be well tolerated in patients with Burkitt lymphoma. This is according to findings presented at the 2022 American Society...
- 15From:Chest (Vol. 113, Issue 1) Peer-Reviewed
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience
Non-small cell lung cancer (NSCLC) is refractory to systemic chemotherapy, compared with small cell lung cancer. Until recently, only five drugs--cisplatin, vindesine, mitomycin, ifosfamide, and vinblastine--could... - 16From:British Medical Journal (Vol. 304, Issue 6831) Peer-ReviewedOvarian, ablation, chemotherapy, and tamoxifen all work Breast cancer will affect an estimated five million women in the next decade. To date, adjuvant systemic treatments have only modestly improved disease free and...
- 17From:Chest (Vol. 109, Issue 5) Peer-ReviewedInduction (neoadjuvant) chemotherapy has become an accepted treatment for stage IIIA (T1-3N2M0) non-small cell lung cancer. In two recent randomized trials, neoadjuvant chemotherapy plus surgery gave an increase in...
- 18From:Breast Cancer Research (Vol. 14, Issue 3) Peer-ReviewedIntroduction Breast cancers of different molecular subtypes have different survival rates. The goal of this study was to identify patients at high risk for local-regional recurrence according to response to...
- 19From:World Journal of Surgical Oncology (Vol. 11, Issue 1) Peer-ReviewedBackground Decision making for adjuvant chemotherapy in stage III colon cancer is based on the TNM system. It is well known that prognosis worsens with higher pN classification, and several recent studies propose...
- 20From:Expert Review of Anticancer Therapy (Vol. 10, Issue 2) Peer-ReviewedAuthor(s): Myra F Barginear [[dagger]â ] 1 , George Raptis 2 Keywords : breast cancer; PARP inhibition; PI3K inhibitors; T-DM1 Breast cancer is the most common non-cutaneous cancer in women in the Western...